An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer
The FASEB Journal · 2024
DOI: 10.1096/fj.202301968r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Mei Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: ErbB Receptors, Immunotoxins, Head and Neck Neoplasms, Immunoglobulin G. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Korea Health Industry Development Institute (KHIDI), National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) is an important target for cancer therapies. Many head and neck cancer (HNC) cells have been reported to overexpress EGFR; therefore, anti‐EGFR therapies have been attempted in patients with HNC. However, its clinical efficacy is limited owing to the development of drug resistance. In this study, we developed an EGFR‐targeting immunotoxin consisting of a clinically proven anti‐EGFR IgG (cetuximab; CTX) and a toxin fragment (LR‐LO10) derived from Pseudomonas exotoxin A (PE) using a novel site‐specific conjugation technology (peptide‐directed photo‐crosslinking reaction), as an alternative option. The immunotoxin (CTX‐LR‐LO10) showed specific binding to EGFR and properties of a typical IgG, such as stability, interactions with receptors of immune cells, and pharmacokinetics, and inhibited protein synthesis via modification of elongation factor‐2. Treatment of EGFR‐positive HNC cells with the immunotoxin resulted in apoptotic cell death and the inhibition of cell migration and invasion. The efficacy of CTX‐LR‐LO10 was evaluated in xenograft mouse models, and the immunotoxin exhibited much stronger tumor suppression than CTX or LR‐LO10. Transcriptome analyses revealed that the immunotoxins elicited immune responses and altered the expression of genes related to its mechanisms of action. These results support the notion that CTX‐LR‐LO10 may serve as a new therapeutic agent targeting EGFR‐positive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.
- Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea.
- Department of Biomedical Sciences, Graduate School, Korea University, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Graduate School of Ajou University, Suwon, Republic of Korea.
- Department of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea.
- School of Biopharmaceutical and Medical Sciences, Sungshin Women's University, Seoul, Republic of Korea.
ORCID-Profile: Mei Huang, Jisoo Park, Jina Seo, Sanghwan Ko, Yoon Hee Yang, Yeaji Lee, Hyo Jeong Kim, Bok-Soon Lee, Yun Sang Lee, Byoung Joon Ko, Sang Teak Jung, Deachan Park, Tae Hyeon Yoo, Chul-Ho Kim
Förderung
- Korea Health Industry Development Institute (KHIDI)
- National Research Foundation of Korea (NRF)
Zitieren
APA
Huang, M., Park, J., Seo, J., Ko, S., Yang, Y. H., Lee, Y., Kim, H. J., Lee, B. S., Lee, Y. S., Ko, B. J., Jung, S. T., Park, D., Yoo, T. H., & Kim, C. H. (2024). An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. The FASEB Journal. https://doi.org/10.1096/fj.202301968r
Vancouver
Huang M, Park J, Seo J, Ko S, Yang YH, Lee Y, et al. An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer. The FASEB Journal. 2024. doi:10.1096/fj.202301968r
BibTeX
@article{Huang2024,
author = {Huang, Mei and Park, Jisoo and Seo, Jina and Ko, Sanghwan and Yang, Yoon Hee and Lee, Yeaji and Kim, Hyo Jeong and Lee, Bok-Soon and Lee, Yun Sang and Ko, Byoung Joon and Jung, Sang Teak and Park, Deachan and Yoo, Tae Hyeon and Kim, Chul-Ho},
title = {An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202301968r}
}
EUVIMED